Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Inhibrx Biosciences, Inc. - Common Stock (NQ:INBX)

78.30 +1.71 (+2.23%)
Streaming Delayed Price Updated: 12:04 PM EST, Feb 24, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Inhibrx Biosciences, Inc. - Common Stock

< Previous 1 2 3 Next >
News headline image
Earnings Scheduled For November 14, 2025 ↗
 
Via Benzinga
News headline image
Unusual volume stocks in Thursday's session ↗
Discover the stocks with unexpected trading volume in today's session on the US markets. 
Via Chartmill
News headline image
The trading volume of these stocks is deviating from the norm in today's session. ↗
Unusual volume stocks are being observed in Tuesday's session. 
Via Chartmill
Why Is INBX Stock Rising Today? ↗
Via Stocktwits
News headline image
INBX Stock Earnings: Inhibrx Beats EPS for Q1 2024 ↗
INBX stock results show that Inhibrx beat analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
News headline image
US Stocks Jump To Records Amid Weak Inflation: Investor Fear Eases, Greed Index Remains In 'Fear' Zone ↗
Stocks hit all-time highs as inflation eased, boosting confidence for Fed rate cut. Fear & Greed Index shows fear, but higher stock prices. 
Via Benzinga
Topics Economy
News headline image
Inhibrx Biosciences Soars Over 90% on Breakthrough Rare Bone Cancer Trial Results
San Diego, CA – October 24, 2025 – Inhibrx Biosciences, Inc. (NASDAQ: INBX) witnessed an extraordinary surge in its stock price today, rocketing by over 94% in early trading, following the announcement... 
Via MarketMinute
News headline image
Here are the top movers in Friday's session. ↗
Let's have a look at what is happening on the US markets one hour before the close of the markets on Friday. Below you can find the top gainers and losers in today's session. 
Via Chartmill
News headline image
Stocks Soar To Records After Weak Inflation, Ford Jumps 10%: What's Moving Markets Friday? ↗
Wall Street surged to fresh all-time highs Friday as a softer-than-expected inflation reading strengthened market conviction that the Federal Reserve will cut interest rates by 25 basis points at its... 
Via Benzinga
Topics Economy
News headline image
12 Health Care Stocks Moving In Friday's Intraday Session ↗
 
Via Benzinga
News headline image
What's going on in today's session ↗
Keep an eye on the top gainers and losers in Friday's session, as they reflect the most notable price movements. 
Via Chartmill
News headline image
Dow Jumps Over 500 Points; US Consumer Sentiment Declines In October ↗
 
Via Benzinga
Topics Stocks
News headline image
Inhibrx Stock Soars on Breakthrough Chondrosarcoma Trial Results: A New Dawn for Rare Cancer Treatment
San Diego, CA – October 24, 2025 – Inhibrx (NASDAQ: INBX) shares have surged dramatically, skyrocketing over 70% in pre-market and after-hours trading, following the announcement of overwhelmingly... 
Via MarketMinute
News headline image
Ford, Inhibrx Biosciences, Comfort Systems, Western Union And Other Big Stocks Moving Higher On Friday ↗
 
Via Benzinga
News headline image
Which stocks are gapping on Friday? ↗
Let's delve into the US markets on Friday and uncover the stocks that are experiencing notable gaps in today's session. Below, you'll find the gap up and gap down stocks. 
Via Chartmill
News headline image
Get insights into the top gainers and losers of Friday's pre-market session. ↗
The US market is yet to commence its session on Friday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Why Intel Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Why Are Inhibrx Biosciences Shares Soaring 76% After Hours? ↗
Inhibrx Biosciences shares surged nearly 76% in after-hours trading Thursday after the company reported positive Phase 2 trial results for its cancer drug Ozekibart. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's After-Market Session ↗
 
Via Benzinga
News headline image
Get insights into the top gainers and losers of Thursday's after-hours session. ↗
After the conclusion of the US market's regular session on Thursday, let's examine the after-hours session and unveil the notable performers among the top gainers and losers. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
 
Via Benzinga
News headline image
Inhibrx Biosciences Beats Earnings ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
Around $2M Bet On Franklin Resources? Check Out These 4 Stocks Executives Are Buying ↗
 
Via Benzinga
News headline image
Over $7M Bet On This Health Care Stock? Check Out These 3 Stocks Executives Are Buying ↗
 
Via Benzinga
News headline image
INBX Stock Earnings: Inhibrx Biosciences Beats EPS for Q2 2024 ↗
INBX stock results show that Inhibrx Biosciences beat analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
News headline image
Top 4 Health Care Stocks That Are Preparing To Pump This Month ↗
 
Via Benzinga
News headline image
The NVDA Earnings Effect And What It Means For The Current Market Momentum ↗
Discover the confluence zone that will make or break the S&P 500 and the preliminary supply (early distribution) you need to be aware of. 
Via Talk Markets
Topics Stocks
News headline image
Is The Stock Market Ready To Plunge? The Warning Signs Are Here... ↗
Find out how to spot the exhaustion of demand and the bearish analogue you could refer to to anticipate the down move. 
Via Talk Markets
News headline image
Sanofi Barrels Into Liver Disease Space With $1.7 Billion Takeover Of Inhibrx ↗
The company is buying Inhibrx, which is working on a treatment for alpha-1 antitrypsin deficiency. 
Via Investor's Business Daily
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.